Background: The purpose of this study was to assess the concordance of real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR) detection of ESR1, PGR, ERBB2, and MKi67 messenger RNA (mRNA) in breast cancer tissues with central immunohistochemistry (IHC) in women treated within the prospective, randomized Austrian Breast and Colorectal Cancer Study Group (ABCSG) Trial 6.
Patients And Methods: We evaluated ESR1, PGR, ERBB2, and MKi67 mRNA expression by Xpert® Breast Cancer STRAT4 (enables cartridge-based RT-qPCR detection of mRNA in formalin-fixed paraffin-embedded tissues) and estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki67 protein expression by IHC [in situ hybridization (ISH) for HER2 IHC 2+] in 1115 surgical formalin-fixed paraffin-embedded specimens from patients of ABCSG Trial 6. Overall percent agreement (concordance), positive percent agreement (sensitivity), and negative percent agreement (specificity) between STRAT4 and IHC were determined for each marker. The primary objective of the study was concordance between STRAT4 mRNA measurements of ESR1, PGR, ERBB2, and MKi67 with central reference laboratory IHC (and ISH for HER2 IHC 2+ cases). Time to distant recurrence was analyzed by Cox models.
Results: All performance targets for ER, PR, and Ki67 were met. For HER2, the negative percent agreement target but not the positive percent agreement target was met. Concordance between STRAT4 and IHC was 98.9% for ER, 89.9% for PR, 98.2% for HER2, and 84.8% for Ki67 (excluding intermediate IHC 10%-20% staining). In univariable and multivariable Cox regression analyses, all four biomarkers tested by either STRAT4 RT-qPCR or by central IHC (ISH) had a comparable time to distant recurrence indicating similar prognostic value.
Conclusions: With the exception of HER2, we demonstrate high concordance between centrally assessed IHC and mRNA measurements of ER, PR, and Ki67 as well as a high correlation of the two methods with clinical outcome. Thus, mRNA-based assessment by STRAT4 is a promising new tool for diagnostic and therapeutic decisions in breast cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358421 | PMC |
| http://dx.doi.org/10.1016/j.esmoop.2021.100228 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ultra-high-resolution brain MRI at 0.55T: bSTAR and its application to magnetization transfer ratio imaging.
Z Med Phys
January 2025
Department of Biomedical Engineering, University of Basel, Allschwil, Switzerland; Department of Radiology, Division of Radiological Physics, University Hospital Basel, Basel, Switzerland.
Purpose: This study aims to evaluate the feasibility of structural sub-millimeter isotropic brain MRI at 0.55 T using a 3D half-radial dual-echo balanced steady-state free precession sequence, termed bSTAR and to assess its potential for high-resolution magnetization transfer imaging.
Methods: Phantom and in-vivo imaging of three healthy volunteers was performed on a low-field 0.
Accuracy of Echocardiographic Cardiac Output Assessment by Critical Care Fellows.
ATS Sch
December 2024
Division of Pulmonary, Critical Care, and Sleep Medicine, New York University Langone Health, New York, New York; and.
Background: Advanced critical care echocardiography comprises a specific set of qualitative and quantitative point-of-care echocardiography skills, including a reliable, noninvasive method to measure cardiac output. This technique requires echocardiographic measurement of left ventricular outflow tract (LVOT) diameter and LVOT velocity time integral (VTI). Although there is a demand among critical care fellows to learn these advanced techniques, there are no data describing the acquisition of mastery in these skills.
View Article and Find Full Text PDFAnalytical Validation of the Labcorp Plasma Complete Test, a Cell-free DNA Comprehensive Genomic Profiling Tool for Precision Oncology.
J Mol Diagn
January 2025
Labcorp Oncology (PGDx), Baltimore, MD 21224.
To help guide treatment decisions and clinical trial matching, tumor genomic profiling is an essential precision oncology tool. Liquid biopsy, a complementary approach to tissue testing, can assess tumor-specific DNA alterations circulating in the blood. Labcorp Plasma Complete is a next-generation sequencing, cell-free DNA comprehensive genomic profiling test that identifies clinically relevant somatic variants across 521 genes in advanced and metastatic solid cancers.
View Article and Find Full Text PDFUltrasound-assessed thigh fat thickness is valid for estimating body fat percentage in Division I collegiate female athletes.
J Sci Med Sport
December 2024
Department of Kinesiology, Michigan State University, USA. Electronic address:
Objectives: Monitoring body composition can help to optimize performance in female athletes. This study aimed to create a conversion equation between dual-energy X-ray absorptiometry-measured body fat percentage and ultrasound-measured subcutaneous thigh fat thickness in Division I female athletes as a more accessible, cost-effective alternative.
Design: Cross-sectional study.
Team resuscitation for paediatrics (TRAP); application and validation of a paediatric resuscitation quality instrument in non-simulated resuscitations.
Resusc Plus
January 2025
University of Colorado, Children's Hospital Colorado, Aurora, CO, USA.
Background: Resuscitation of paediatric cardiac and respiratory arrest is a high-stakes and low frequency event in the paediatric emergency department. Resuscitation team performance assessment tools have been developed and validated for use in the simulation environment, but no tool currently exists to evaluate clinical performance in non-simulated, live paediatric resuscitations.
Methods: This is a validation study assessing inter-rater reliability of a novel assessment tool of clinical performance of non-simulated resuscitations, the Team Resuscitation for Paediatrics tool.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!